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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.11.005Abstract Single or multilineage bone marrow failure can be a serious health problem caused by hereditary and
non-hereditary causes such as exposure to drugs or environmental toxins. Normal hematopoiesis requires the
integrity of several pathways including the THPO–MPL pathway. Over the last two decades, significant
advances in the understanding of normal and abnormal functions of this and related pathways have led to novel
diagnostic and therapeutic options.
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Aplastic anemia; Bone marrow failure; Thrombocythemia; Myelofibrosis; Eltrombopag; RomiplostimSingle or multilineage bone marrow failure iscaused by hereditary and non-hereditary causessuch as exposure to drugs or environmental
toxins, and can be a serious health problem. Normal
hematopoiesis requires the integrity of several path-
ways including the THPO–MPL pathway. Over
the last two decades, signiﬁcant advances in the
understanding of normal and abnormal functions of
this and related pathways have led to novel diagnostic
and therapeutic options. The discovery of v-mpl (an
oncogene from the murine myeloproliferative leuke-
mia virus) in 1990 was quickly followed by the iden-
tiﬁcation of its human homolog, c-MPL, which
encodes a protein homologous with members of the
hematopoietic receptor superfamily.1 In 1994, the
cMPL ligand, thrombopoietin (THPO), was cloned.2
MPL encodes a 635 amino acid transmembrane pro-
tein MPL or CD110. Upon binding of THPO, MPL
dimerizes and activates the JAK family of non-recep-
tor tyrosine kinases, which in turn activate the signal
transducer and activator of transcription (STAT) and
MAPK families as well as SHC adaptor protein, lead-
ing to transcription of genes that regulate cell prolifer-
ation and survival (Figure 1).3 Intracellular trafﬁckingof MPL also follows a complex pathway as the
mature, fully glycosylated form reaches the surface
through the conventional ER-Golgi pathway while
the immature form is routed through an autophagic
pathway for unconventional secretion. Both forms
can be recycled or stored in calcium-dependent and
independent compartments capable of fusion with
the plasma membrane and in some cells, such as
K562 cells, MPL is packaged into exosomes and
secreted (Figure 1).4 Thrombopoietin (THPO), a
critical hematopoietic stem cell (HSC) regulator, is
a growth factor which is primarily involved in regulat-
ing thrombopoiesis and has been recently implicated
in the pathogenesis of non-hematological disorders
such as sepsis since its levels are signiﬁcantly elevated
in affected patients, and correlate with sepsis severity.5
Unlike other HSC growth factors, THPO ensures
HSC chromosomal integrity and functions in
response to c-irradiation by regulating DNA-damage
response through increased DNA–protein kinase
(DNA-PK) phosphorylation and non-homologous
end-joining (NHEJ) repair efﬁciency and ﬁdelity,
which may help improve the safety of anticancer
DNA agents.6arter 2015
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Figure 1. THPO–MPL Signaling and MPL Trafficking. Binding of THPO ligand or THPO analogs to MPL receptor activates the JAK/STAT pathway as
shown here which induces transcription of genes that regulate cell proliferation and survival. The complex MPL trafficking pathway includes the
conventional secretory pathway for the mature and glycosylated form while the autophagic pathway is used by the immature form. The molecular
characteristics of THPO and MPL genes are shown in the boxes in the left upper corner.
THPO–MPL PATHWAY AND BONE MARROW FAILURE editorialMutations in THPO, its receptor MPL, and
downstream targets are associated with a wide spec-
trum of clinical disorders ranging from thrombocythe-
mia and thrombocytopenia to more generalized effects
on trilineage hematopoiesis in the form of aplastic
anemia and myeloﬁbrosis (MF) (Table 1). Thrombo-
cythemia, or thrombocytosis, is a genetically heteroge-
neous myeloproliferative disorder (MPD)
characterized by excessive platelet production result-
ing in increased numbers of circulating platelets and
can be associated with thrombotic or hemorrhagic
episodes, and occasional leukemic transformation.
Approximately 50–60% of patients with essential
thrombocythemia or primary myeloﬁbrosis carry a
mutation in Janus kinase 2 (JAK2), especially JAK2
V617F which can cause monotonous activation of
the downstream STAT pathway without any other
trigger. An additional 5–10% have activating muta-
tions in MPL. In most of the remaining 30–45% of
patients without JAK2 or MPL mutations, somatic
calreticulin (CALR) gene mutations were detected.7,8
The identiﬁed CALR exon 9 most common deletions
or insertions (type 1 or c.1092_1143del, p.L367 fs*46
and type 2 or c.1154_1155insTTGTC, p.K385 fs*47)
cause a frameshift to the same alternative reading
frame and generate a novel C-terminal peptide in
the mutant calreticulin. Overexpression of the type
1 CALR deletion cause activation of STAT5, result-
ing in cytokine-independent growth in vitro.7,8
Mutant calreticulin was observed in the endoplasmicHematol Oncol Stem Cell Ther 8(1) First Quarter 2015reticulum without increased cell-surface or Golgi
accumulation. In general, patients with mutated
CALR presented with higher platelet counts, lower
hemoglobin levels, and had a lower risk of thrombosis
as well as longer overall survival than patients with
mutated JAK2.7,8 The MPL K39 N mutation, which
is restricted to African Americans, is associated with
thrombocytosis both in heterozygous and homozy-
gous states, albeit more severely.9 Other genes known
to be mutated in patients with thrombocythemia
include TET2, ASXL1, SH2B3, SF3B1 and a putative
X-linked gene locus (THCYTX) which was sus-
pected in a single large consanguineous Saudi Arabian
family.10 However, autosomal recessive inheritance
was not excluded in that family. The MPL gain-of-
function mutation (W515L/K) was detected in 5–
10% of patients with MF.11 Mutations in several yet
unknown pathogenetic and modiﬁer genes likely con-
tribute to disease diversity and phenotypic variability
of MF.
Congenital amegakaryocytic thrombocytopenia
(CAMT) is a rare disorder expressed in infancy and
characterized by isolated thrombocytopenia and
megakaryocytopenia without physical anomalies. In
approximately 60% of these patients (type I) with a
more severe form of CAMT, there is early progres-
sion to pancytopenia unlike type II patients who dis-
play a transient improvement in their platelet counts
during infancy, followed by the development of pancy-
topenia in early childhood. The bone marrow biopsy7
Table 1. Genes involved in the THPO-MPL pathway. § Known homozygous recessive THPO-MPL mutations reported thus far in patients with
aplastic anemia are shown in the table. The mutation list for genes in this pathway can be found at ClinVar http://www.ncbi.nlm.nih.gov/clinvar/
and COSMIC http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ databases. So far, only somatic mutations in CALR and JAK2 have been
described.26
Gene (aliases) Location Phenotypes and mutations§
THPO (Thrombopoietin;
cMPL ligand)
chr3q27.1:184371935–
184378208 (NM_000460)
Thrombocythemia, thrombocytopenia, aplastic anemia (c.112C>T, R17C); thrombocytosis
associated with limb defects (185G>T; c.13+1 G>C)
c-MPL (Thrombopoietin
receptor; CD110)
chr1p34.2:43337804–
43354464 (NM_005373)
Thrombocytosis, congenital amegakaryocytic thrombocytopenia (CAMT), aplastic anemia
(c.1248G>A p.W416X; c.1180 C>T p.P394S), myeloproliferative disease (MPD)
CALR (calreticulin) chr19p13.13:12938600–
12944490 (NM_004343)
Myelofibrosis (somatic), thrombocythemia (somatic), myeloproliferative disease (MPD)
JAK2 (tyrosine-protein
kinase, Janus Kinase)
chr9p24.1:4985245–5128183
(NM_004972)
Somatic mutations in erythrocytosis, acute myelogenous leukemia, myelofibrosis,
polycythemia vera, thrombocythemia 3, Budd-Chiari syndrome
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edly decreased numbers of megakaryocytes and no
dysplastic changes. Both heterozygous and homozy-
gous inactivating mutations in MPL have been
described in association with CAMT.12 On the other
hand, far fewer THPO mutations associated with
thrombocytopenia have been reported in the litera-
ture. Mandrile et al. and Dasouki et al. recently
reported the cases of four unrelated young individuals
with a recurring microdeletion syndrome involving
the THPO locus at chr3q27.1, which is associated
with mild asymptomatic thrombocytopenia.13,14 In
addition, Dasouki et al. described an inactivating
homozygous point mutation (THPO R17C) in two
Micronesian siblings with aplastic anemia, where the
heterozygous parents also had mild asymptomatic
thrombocytopenia.15
Aplastic anemia is a clinically and molecularly het-
erogeneous disorder.16 Our team and others have
demonstrated the utility of exome sequencing in iden-
tifying novel genetic causes of aplastic anemia, namely
mutations in MPL receptor (Walne et al. 2012) and
its ligand THPO (Dasouki et al. 2013).15,17 In addi-
tion to the homozygous mutation found in a consan-
guineous Tunisian family, Walne et al. examined 33
uncharacterized index cases with aplastic anemia
(<13 years old) using denaturing high performance
liquid chromatography (HPLC). Only one additional
novel homozygous MPL mutation was identiﬁed in
another consanguineous Pakistani family. Subse-
quently, Wang et al. reported absence of MPL muta-
tions in 83 Japanese children with aplastic anemia.18
Taken together, so far, the mutation studies of
MPL in 118 patients with aplastic anemia yieldedpathogenic recessive mutations in only two patients
(1.7%), suggesting that recessive mutations in MPL
are not a major cause of aplastic anemia, which is con-
sistent with the conclusions of Wang et al.
MPL agonists eltrombopag and romiplostim, also
known as THPO analogs, have been approved for
clinical use in patients with idiopathic thrombocyto-
penia. Eltrombopag was reported to be beneﬁcial in
44% of a group of patients with idiopathic aplastic
anemia.19 More recently, either eltrombopag or romi-
plostim had been successfully used in a small number
of patients with complex clinical problems including
thrombocytopenia in association with hepatitic C
virus (HCV) cirrhosis and hepatocellular carcinoma,
liver transplantation due to primary sclerosing cholan-
gitis, and HSC transplantation in a patient with X-
linked chronic granulomatous disease.20–22 However,
as a result of our discovery of a mutation in THPO
causing aplastic anemia and the report by Olnes
et al. showing clinical response in some patients with
idiopathic aplastic anemia, we speculate that aplastic
anemia caused by mutations in THPO may be more
common and may be responsive to therapy with
THPO analogs. If proven, patients who respond to
THPO analogs will not need more invasive and risky
therapeutic interventions such as bone marrow trans-
plantation. Also, the identiﬁcation of an activating
somatic mutation in JAK2 V617F in approximately
half of the patients with myeloﬁbrosis (MF) has ush-
ered in a new era of understanding its pathophysiol-
ogy. This discovery has become the foundation for
the development and use of novel JAK2 inhibitors
in patients with MF. Examples of newly developed
JAK2 inhibitors include ruxolitinib and fedratinib,Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
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which were reported to signiﬁcantly reduce spleno-
megaly and symptom burden in patients with MF.23
Several clinical trials using recombinant human
thrombopoietin (rhTHPO) with or without other
immunomodulatory agents (rituximab, steroids, che-
motherapy) in patients with primary immune throm-
bocytopenia (ITP) are underway. The investigational
THPO analog SB-497115 and eltrombopag, both of
which are MPL agonists, are also being studied in
patients with thrombocytopenia due to hepatitis C,
aplastic anemia, myelodysplastic syndrome (MDS),
and in the prevention of thrombocytopenia after
ﬁrst-line chemotherapy. JAK2 inhibitors (erlotinib,
ruxolitinib, panobinostat, lestaurtinib, AZD1480,
anagrelide hydrochloride, SB1518, SAR302503),
HDAC Inhibitor (givinostat) as well as anti-TGFb
antibody are being evaluated in patients with various
myeloproliferative disorders (clinicaltrials.gov).24
Our studies as well as the studies of Walne et al.
and Olnes et al., together with the known importantHematol Oncol Stem Cell Ther 8(1) First Quarter 2015role of JAK2 somatic mutations in patients with var-
ious MPD disorders, highlight the important role of
THPO-MPL pathway in trilineage hematopoiesis.
Additional studies – particularly genomic and tran-
scriptomic analyses using the powerful next genera-
tion sequencing – are needed to identify novel
causes of aplastic anemia, which will enhance diagno-
sis, pathogenetic understanding, and management.
Also, the recent identiﬁcation of the zebraﬁsh
thpo and its functional role in the differentiation of
thrombocytes from HSCs may position the
zebraﬁsh as an excellent model to investigate diseases
caused by dysregulated erythro- and thrombopoietic
differentiation.25CONFLICT OF INTEREST
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